M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed
Merck's verubecestat has flopped in a second Phase III Alzheimer's trial; investors are anticipating M&A or licensing deals soon to bring something new into the big pharma's development portfolio.
You may also be interested in...
An interim look at two Phase II/III trials showed the drug worsened cognition in people at high risk of developing Alzheimer's disease. This is the 16th failure of a BACE-targeting therapy.
Elenbecestat can continue in the Phase III MISSION AD studies in Alzheimer’s, the data safety monitoring board says.
Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.